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Understanding the mechanisms that prevent or account
for the production of autoreactive B cells may suggest new
approaches to control disease and design more specific
and sustained therapies.Indeed, an important role for B
cells in autoimmune diseases has recently been demon-
strated by successful treatment of rheumatoid arthritis
(RA), multiple sclerosis (MS), and type 1 diabetes (T1D)
patients with anti-CD20 monoclonal antibodies that elimi-
nate B cells. However, the underlying mechanisms by
which B cells may promote the development of autoim-
mune diseases remain poorly understood. Studying B cell
tolerance in PID patients allowed us to identify molecules
and pathways that regulate the removal of developing
autoreactive B cells that is impaired in patients with
RA, systemic lupus erythematosus (SLE) and T1D. For
instance, alterations in B-cell receptor (BCR) signaling
threshold in patients lacking functional BTK, CD19, or
molecules mediating Toll-like receptor (TLR) signaling
such as IRAK-4, MyD88, and UNC-93B result in a defec-
tive central B cell tolerance checkpoint and in the abnor-
mal negative selection of developing autoreactive B cells
[1]. In addition, we identified a major and previously
unsuspected role for activation-induced cytidinedeaminase
(AID), an enzyme required for class switch recombination
(CSR) and somatic hypermutation (SHM), in the removal
of developing autoreactive B cells in humans [2].
These observations on rare PID patients are very rele-
vant to the development of common autoimmune diseases
in that variations in many genes encoding several compo-
nents of the BCR signaling pathways such as PTPN22,
seem to be associated with RA, SLE, or T1D.Indeed, the
PTPN22 risk allele, which encodes an R620W variant
inducing decreased BCR signaling, is sufficient to alter the
removal of developing autoreactive B cells in healthy
donors [3]. Thus, decreased BCR signaling favors the
development of autoimmunity by failing to induce central
B cell tolerance mechanisms after binding to self-antigens
and results in the accumulation of large number of auto-
reactive B cells in the periphery [1,3].In addition, gene
array experiments analyzing mature naïve B cells display-
ing PTPN22 risk allele(s) revealed that the association
strength of PTPN22 for autoimmunity may not only be
due to the impaired removal of autoreactive B cells but
also to the upregulation of genes such as CD40, TRAF1,
and IRF5, which encode proteins that promote B cell acti-
vation and have been identified as susceptibility genes
associated with autoimmune diseases [3]. These data
demonstrate that early B cell tolerance defects in autoim-
munity can result from specific polymorphisms and pre-
cede the onset of disease.
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